Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S.

Oncologist. 2016 Aug 26. pii: theoncologist.2016-0049. [Epub ahead of print]

PMID:
27566247
2.

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.

Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, Ali SM, Yair R, Soussan-Gutman L, Bokstein F.

J Neurooncol. 2016 Aug 16. [Epub ahead of print]

PMID:
27531351
3.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly R, Cochran R, Croessmann S, Clark T, Gocke CD, Jeter SC, Kennedy M, Lauring J, Lee J, Lipson D, Miller V, Otto G, Rosner GL, Ross JS, Slater SA, Stephens PJ, VanDenBerg DA, Wolff AC, Young L, Zabansky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2016 Aug 3. pii: clincanres.1543.2016. [Epub ahead of print]

PMID:
27489289
4.

Imaging of Spine Trauma.

Shah LM, Ross JS.

Neurosurgery. 2016 Jul 12. [Epub ahead of print]

PMID:
27404215
5.

Imaging of Degenerative and Infectious Conditions of the Spine.

Shah LM, Ross JS.

Neurosurgery. 2016 Sep;79(3):315-35. doi: 10.1227/NEU.0000000000001323.

PMID:
27352276
6.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

7.

Regarding "Circulatory dynamics of the cauda equina in lumbar canal stenosis using dynamic contrast-enhanced magnetic resonance imaging".

Ross JS.

Spine J. 2016 Jun;16(6):794. doi: 10.1016/j.spinee.2016.01.196. No abstract available.

PMID:
27342711
8.

Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations.

Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham D, Washburn D, Wong S, Chmiekecki J, Yelensky R, Lipson D, Miller V, Serracino HS, Stephens PJ, Ross JS, Bowles DW.

Clin Cancer Res. 2016 Jun 22. pii: clincanres.2568.2015. [Epub ahead of print]

PMID:
27334835
9.

A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient.

Ali SM, Watson J, Wang K, Chung JH, McMahon C, Ross JS, Dicke KA.

Case Rep Oncol. 2016 Feb 18;9(1):112-8. doi: 10.1159/000443371. eCollection 2016 Jan-Apr.

10.

Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets.

Johnson A, Morosini D, Vergilio JA, Yelensky R, Rosenzweig M, Khaira D, Ali SM, Palma N, Lipson D, Juhn F, Erlich R, Stephens PJ, Ross JS, Miller VA, Wang K.

Br J Haematol. 2016 Jun 12. doi: 10.1111/bjh.14157. [Epub ahead of print] No abstract available.

PMID:
27291498
11.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

PMID:
27284958
12.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

PMID:
27245569
13.

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma.

Joshi M, Vasekar M, Grivas P, Emamekhoo H, Hsu J, Miller VA, Stephens PJ, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK.

Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9449. [Epub ahead of print]

14.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ.

Oncology. 2016;90(6):339-46. doi: 10.1159/000445978. Epub 2016 May 21.

PMID:
27207748
15.

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.

Ravi V, Sanford EM, Wang WL, Ross JS, Ramesh N, Futreal A, Patel S, Stephens PJ, Miller VA, Ali SM.

J Natl Compr Canc Netw. 2016 May;14(5):499-502.

PMID:
27160228
16.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S.

J Clin Invest. 2016 Jun 1;126(6):2334-40. doi: 10.1172/JCI84940. Epub 2016 May 9.

PMID:
27159395
17.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.

Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.

PMID:
27151654
18.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, VavalĂ  T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

PMID:
27102076
19.

Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, Balasubramanian S, Stephens PJ, Schultz N, Oren M, Tang L, Kelsen D.

Gastroenterology. 2016 Aug;151(2):278-287.e6. doi: 10.1053/j.gastro.2016.04.001. Epub 2016 Apr 8.

PMID:
27063727
20.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.

Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.

PMID:
27048246
Items per page

Supplemental Content

Loading ...
Write to the Help Desk